Advertisement

Cambridge biotech Tolerx Inc. said today that it has initiated a Phase 1 clinical trial of its TRX518, a therapy designed to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.

The trial will evaluate the use of ascending single doses of TRX518 in patients with malignant melanoma, and will be conducted at Memorial Sloan-Kettering Cancer Center. The trial is supported by research funding to Tolerx from the Cancer Research Institute and trials management expertise from the Ludwig Institute for Cancer Research Ltd. through its Cancer Vaccine Acceleration Fund (CVAF).

SOURCE

Advertisement
Advertisement